Facebook
Twitter
LinkedIn
ForwardOvercoming Resistance Mechanisms in Malignant Brain Tumors- Enduring
Medical staff requested a series of lectures on the landscape of cancer care. Perspectives from thought leaders helps to revitalize the medical staff and develop innovative ideas on ways they can improve and impact patient care as well as research methods and technology, in addition to creating connections which may result in the eventual treatment options which may cure cancer.
Target Audience
The activity content is oriented to address the educational needs of physicians, nurses and all healthcare professionals interested in the subject matter.
Learning Objectives
- Discuss resistance induced therapies in glioblastoma (GBM).
- Discuss current and possible future treatment modalities in GBM.
- Examine the importance of T Cells when considering therapies for glioblastomas.
Additional Information
| Attachment | Size |
|---|---|
 AB 1195 & AB 241 BIBLIO HEADER_Linda M. Liau, MD, PhD, MBA.pdf | 164.39 KB |
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months. Faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships with any ineligible company, which is defined as any entity whose primary business is to produce, market , sell, re-sell or distribute healthcare products used by or on patients. To comply with more intense scrutiny by accreditation agencies, content whose faculty has disclosed any relevant financial relationships with an ineligible company, have been peer reviewed prior to presenting and any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Linda M. Liau has indicated the following relevant financial relationships: Grant/Research Support from Merck, and Northwest Biotherapeutics; is a Consultant for ImmPACT Bio, and Insightec; and is a Stock/Shareholder of ClearPoint Neuro.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer Nothing to Disclose: Patricia Aoun, MD; Chandana Banerjee, MD; Daneng Li, MD; Anna Pawlowska, MD; Michael Rosenzweig, MD; Crystal Saavedra; Behrouz Salehian, MD; Gagandeep Singh, MD; Sepidah Shayani, PharmD; Shanmuga Subbiah, MD
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
This activity will include a discussion of the off-label or investigational use of Pembrolizumab and Poly-ICLC.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
This activity has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hour toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Overcoming Resistance Mechanisms in Malignant Brain Tumors- Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance
You must be logged in to access this Enduring.
If you are a New User, please create an account first, by clicking on "Register".
Once Logged in:
Click on "Start Activity" to access the educational content for this Enduring activity.
ACTIVITY INSTRUCTIONS
In order to earn credit for this activity, participants must:
- Read learning objectives and faculty disclosures
- View Enduring Activity Video
- Complete the evaluation
Upon satisfactory completion, you will have the option to receive a print out of your certificate.
If you have questions regarding this process, please contact the City of Hope Continuing Medical Education at 626-218-5622 or cme@coh.org
Estimated timeframe for completion of this activity, including the time to complete the evaluation is 1.0 hour.